We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Invited Critique |

First-Line Chemotherapy vs Bowel Tumor Resection Plus Chemotherapy for Patients With Unresectable Synchronous Colorectal Hepatic Metastases—Invited Critique

Gregory Kennedy, MD; Heidi Nelson, MD
Arch Surg. 2008;143(4):358. doi:10.1001/archsurg.143.4.358.
Text Size: A A A
Published online


The optimal management strategy for asymptomatic patients presenting with unresectable stage IV colorectal cancer remains controversial. Whether or not resection of the primary tumor provides a benefit to the patient of survival or prevention of secondary complications remains to be conclusively addressed. Many have devoted retrospective studies to this question,14 including the report by Galizia and colleagues, who make a compelling argument for proceeding with resection of the primary tumor before initiating chemotherapy. In their report, patients treated medically suffered a significant rate of secondary complications attributable to the primary tumor. Galizia et al ultimately concluded that resection of the primary tumor should be undertaken to reduce the risk of severe complications related to the unresected bowel tumor and to provide better median survival times. Although some authors such as Ruo et al1 report similar findings and support the surgery-first approach, others report that complication rates as low as 3% to 15% can be achieved without surgery first.24 Indeed, a review of the literature demonstrates that one can support surgery followed by chemotherapy or chemotherapy alone as treatment for this group of patients (ie, equipoise).

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles

Care at the Close of Life: Evidence and Experience
The Role of Chemotherapy at the End of Life: "When Is Enough, Enough?"

Care at the Close of Life: Evidence and Experience
Chemotherapy and Hormonal Therapy